Everest Organics Limited has announced the approval of its unaudited financial results for the quarter and nine months ended December 31, 2025. The company's Board of Directors convened on February 14, 2026, to review and approve the quarterly financial performance under Regulation 33 of the SEBI Listing Regulations.

Board Meeting Details

The board meeting was conducted on Saturday, February 14, 2026, with proceedings extending from 08:45 PM to 01:00 AM. The meeting was held in compliance with Regulation 29, 30, 33 and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Approvals and Documentation

During the meeting, the Board of Directors approved and took on record two significant items:

Regulatory Compliance

The announcement was made pursuant to the SEBI Listing Regulations, ensuring full compliance with disclosure requirements. The communication was addressed to the Listing Compliance Department of BSE Limited at Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai. Company Secretary and Compliance Officer Shweta Singh signed the official communication, which was digitally authenticated on February 15, 2026, at 01:06:27 +05'30'.

Information Accessibility

Everest Organics Limited has made the approved financial information available on its official website at www.everestorganicsltd.com , ensuring transparency and accessibility for stakeholders and investors. The company maintains its commitment to regulatory compliance and timely disclosure of material information to the stock exchanges.

Everest Organics Limited has successfully completed its postal ballot process, with all three special resolutions receiving overwhelming shareholder approval of 99.99%. The pharmaceutical company declared the results on December 17, 2025, following the conclusion of remote e-voting on December 16, 2025.

Postal Ballot Overview

The postal ballot was conducted under Section 110 of the Companies Act, 2013, with the notice dated November 12, 2025. Y. Ravi Prasada Reddy (Membership No. FCS5783), Proprietor of RPR Associates, served as the appointed scrutinizer for the remote e-voting process. The company had 8,047 total shareholders on the record date of November 14, 2025.

Resolution Results

All three special resolutions were passed with remarkable shareholder support, achieving 99.99% approval rates. The voting results demonstrate strong confidence in the company's leadership decisions and board restructuring initiatives.

Resolution 1: Director Appointment

Appointment and remuneration payable to Mr. Venkata Satya Subbarao Pachigolla (DIN: 08363668) as Whole-Time Director (Executive Director) effective November 12, 2025.

Resolution 2: Independent Director Designation

Change in designation of Mr. Kirankumar Rampally (DIN: 07621817) from Non-Executive Non-Independent to Non-Executive Independent Director effective November 12, 2025.

Resolution 3: Director Designation Change

Change in designation of Mr. Prasad Venkata Satya Sundara Srikakolapu (DIN: 08304477) from Non-Executive Independent Director to Non-Executive Non-Independent Director effective November 12, 2025.

Detailed Voting Statistics

The postal ballot witnessed participation from 40 members who exercised their voting rights through remote e-voting. All resolutions received identical voting patterns with overwhelming support from shareholders across all categories.

Company Information

Everest Organics Limited operates as an ISO 9001:2015 and WHO GMP certified pharmaceutical company. The company maintains its corporate office at Dwaraka Heights, Jubilee Enclave, Madhapur, Hyderabad, with manufacturing facilities at Aroor Village, Sadasivpet Mandal, Sangareddy District, Telangana. Company Secretary Shweta Singh signed the compliance document confirming the successful completion of the postal ballot process and submitted the results to BSE Limited.